LM11A-31
Based on 7 publication(s) in Google Scholar
LM11A-31, a non-peptide p75NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist. LM11A-31 is an amino acid derivative with high blood-brain barrier permeability and blocks p75-mediated cell death. LM11A-31 reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.88%
- CAS No.: 102562-74-3
- Formule: C12H25N3O2
- Masse moléculaire:243.35
-
Stockage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Neuronal Signaling Compound Library
HY-L013
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) LM11A-31
More- Cell Genom. 2024 Aug 26:100642. [Abstract]
- Mol Neurobiol. 2024 Apr;61(4):2033-2048. [Abstract]
- Glia. 2022 May;70(5):892-912. [Abstract]
- Exp Neurol. 2024 Feb:372:114618. [Abstract]
- Exp Neurol. 2023 Jan:359:114161. [Abstract]
- bioRxiv. 2024 Apr 5:2024.04.03.587970. [Abstract]
- Research Square Preprint. 2021 Oct.
Activité biologique
LM11A-31 (orally; 50 or 75 mg/kg) administered for 3 months starting at 6-8 months of age prevents and/or reverses atrophy of basal forebrain cholinergic neurites and cortical dystrophic neurites in mid-stage male APPL/S mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 J mice[1].
-
Dosage:50 mg kg/day
-
Administration:Oral gavage; for 4 weeks
-
Result:Mitigated proNGF accumulation and preserved BRB integrity.
Chemical Information
-
CAS No. 102562-74-3
-
Appearance Solid
-
Masse moléculaire 243.35
-
Formule C12H25N3O2
-
Color White to off-white
-
SMILES
CC[C@H](C)[C@H](N)C(NCCN1CCOCC1)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Cell Genom
ABCA7-dependent induction of neuropeptide Y is required for synaptic resilience in Alzheimer's disease through BDNF/NGFR signaling. [Abstract]2024 Aug 26:100642. PMID: 39216475 -
Mol Neurobiol
Surfeit Locus Protein 4 as a Novel Target for Therapeutic Intervention in Cerebral Ischemia-Reperfusion Injury. [Abstract]2024 Apr;61(4):2033-2048. PMID: 37843800 -
Glia
Astrocytic p75NTR expression provoked by ischemic stroke exacerbates the blood-brain barrier disruption. [Abstract]2022 May;70(5):892-912. PMID: 35064700 -
Exp Neurol
Axonal injury mediated by neuronal p75NTR/TRAF6/JNK pathway contributes to cognitive impairment after repetitive mTBI. [Abstract]2024 Feb:372:114618. PMID: 38029807 -
Exp Neurol
The p75 neurotrophin receptor inhibitor, LM11A-31, ameliorates acute stroke injury and modulates astrocytic proNGF. [Abstract]2023 Jan:359:114161. PMID: 35787888 -
bioRxiv
Modulation of the p75NTR during adolescent alcohol exposure prevents cholinergic neuronal atrophy and associated acetylcholine activity and behavioral dysfunction. [Abstract]2024 Apr 5:2024.04.03.587970. PMID: 38617368 -
Solvant et solubilité
DMSO : 116.67 mg/mL (479.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Elshaer SL, et al. Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinalvascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway. Diabetologia. 2019 Aug;62(8):1488-1500. [Content Brief]
[2]. Simmons DA, et al. A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression. PLoS One. 2014 Aug 25;9(8):e102136. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.1093 mL | 20.5465 mL | 41.0931 mL | 102.7327 mL |
| 5 mM | 0.8219 mL | 4.1093 mL | 8.2186 mL | 20.5465 mL | |
| 10 mM | 0.4109 mL | 2.0547 mL | 4.1093 mL | 10.2733 mL | |
| 15 mM | 0.2740 mL | 1.3698 mL | 2.7395 mL | 6.8488 mL | |
| 20 mM | 0.2055 mL | 1.0273 mL | 2.0547 mL | 5.1366 mL | |
| 25 mM | 0.1644 mL | 0.8219 mL | 1.6437 mL | 4.1093 mL | |
| 30 mM | 0.1370 mL | 0.6849 mL | 1.3698 mL | 3.4244 mL | |
| 40 mM | 0.1027 mL | 0.5137 mL | 1.0273 mL | 2.5683 mL | |
| 50 mM | 0.0822 mL | 0.4109 mL | 0.8219 mL | 2.0547 mL | |
| 60 mM | 0.0685 mL | 0.3424 mL | 0.6849 mL | 1.7122 mL | |
| 80 mM | 0.0514 mL | 0.2568 mL | 0.5137 mL | 1.2842 mL | |
| 100 mM | 0.0411 mL | 0.2055 mL | 0.4109 mL | 1.0273 mL |
LM11A-31 Related Classifications
HY-117088 Related Classifications
Powered by Bioz